| abstract |
The present invention relates to a ras-farnesyl transferase inhibitor of the general formula wherein n = 0 or 1; R1 is chloro, bromo, phenyl, pyridyl or cyano; R2 is aralkyl; R3 is alkyl, aryl or substituted aryl or heterocyclic group Z1 -CO, -SO2-, -C (= O) -O- or -SO2NR5-; R5 is a complex consisting of a hydrogen atom, an alkyl or substituted alkyl group or a pharmaceutically acceptable salt thereof and a BÉTA cyclodextrin-7-sulfobutyl ether or 2- (hydroxypropyl) -BÉTA cyclodextrin. The complex unexpectedly provides good water solubility and stability to the aras-farnesyl transferase inhibitor and allows intravenous administration as an antitumor agent. HE |